LAF-237 (Novartis).

Abstract

Novartis is developing LAF-237, one of a series of orally active dipeptidylpeptidase IV inhibitors, as a potential once daily therapeutic agent for type 2 diabetes. Phase III trials began in the first quarter of 2004.

• Authors: Daniela Barlocco
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 5 Issue 10 Pg. 1094-100 (Oct 2004) ISSN: 1472-4472 [Print] England
• PMID: 15535431 (Publication Type: Journal Article, Review)

Chemical References

• 1-(((3-hydroxy-1-adamantyl)amino)acetyl)-2-cyanopyrrolidine
• Protease Inhibitors
• Pyrrolidines
• Dipeptidyl Peptidase 4
• Adamantane

Topics

• Adamantane (analogs & derivatives, pharmacokinetics, pharmacology, therapeutic use)
• Animals
• Clinical Trials as Topic
• Diabetes Mellitus, Type 2 (drug therapy, enzymology)
• Dipeptidyl Peptidase 4 (metabolism)
• Humans
• Protease Inhibitors (pharmacokinetics, pharmacology, therapeutic use)
• Pyrrolidines (pharmacokinetics, pharmacology, therapeutic use)
• Structure-Activity Relationship
• Treatment Outcome